Skip to main content
Top
Published in: Clinical Rheumatology 3/2024

03-02-2024 | Cytokines | Original Article

Myofibroblast and pro-fibrotic cytokines in fibrosis of IgG4-related disease (IgG4-RD) patients from South Asia: preliminary data

Authors: Josna Joseph, V. Prabhu, Meera Thomas, Reka Karuppusami, Thomas Alex Kodiatte, Rajiv Michael, Manbha L. Rymbai, John Mathew

Published in: Clinical Rheumatology | Issue 3/2024

Login to get access

Abstract

Introduction

Fibrosis is a typical pathological characteristic in IgG4-RD patients and often irreversible. There exists a lack of suitable markers for detection of earlier onset of fibrosis in various organs in IgG4-RD patients. Hence, this study aims at analysing ambispectively the myofibroblasts and the pro-fibrotic cytokines, IFN gamma and IL-33 involved in IgG4-RD associated fibrosis in South Asian patients.

Method

Archived biopsy samples of definite/probable/possible cases of IgG4-RD, classified according to diagnostic criteria, taken from patients who attended the OPD and IPD of our tertiary care centre during January 2015–January 2020 were chosen for this study. The paraffin sections were examined qualitatively for fibrosis and the excessive collagen deposition by Hematoxylin & Eosin and Masson’s Trichrome staining. Also, the presence of alpha-Smooth muscle actin (α-SMA) expressing myofibroblasts and the involvement of pro-fibrotic cytokines (IFN-gamma, IL-33) were assessed by Immunohistochemistry and scored semi-quantitatively (+mild, ++moderate, +++ severe). Serum IL-33 levels were analysed by indirect Elisa (R & D Systems).

Results

Myofibroblasts were present in 10/12 biopsy samples, in moderate levels in 4 (33%) and very high levels (+++) in 3 (25%) of the patients. IFN-gamma was expressed at low levels in 6 (50%) and absent in 6 (50%). All patients showed IL-33 expression with very high levels in tissue (6, 50%), as well as in serum samples.

Conclusion

The findings of this study reinforce the role of myofibroblasts and profibrotic cytokines like IL-33 in fibrosis of Ig4-RD patients, pointing to their potential as earlier predictive markers of onset and extent of fibrosis.
Literature
1.
go back to reference Brito-Zerón P, Ramos-Casals M, Bosch X, Stone JH (2014) The clinical spectrum of IgG4-related disease. Autoimmun Rev 13(12):1203–1210CrossRefPubMed Brito-Zerón P, Ramos-Casals M, Bosch X, Stone JH (2014) The clinical spectrum of IgG4-related disease. Autoimmun Rev 13(12):1203–1210CrossRefPubMed
2.
go back to reference Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Modern Rheumatol 22(1):21–30CrossRef Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Modern Rheumatol 22(1):21–30CrossRef
3.
go back to reference Uchida K, Masamune A, Shimosegawa T, Okazaki K (2012) Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol 2012:1–5CrossRef Uchida K, Masamune A, Shimosegawa T, Okazaki K (2012) Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol 2012:1–5CrossRef
4.
go back to reference Wallace ZS, Miles G, Smolkina E, Petruski-Ivleva N, Madziva D, Cook C et al (2023) Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults. Ann Rheum Dis 82(7):957–962CrossRefPubMed Wallace ZS, Miles G, Smolkina E, Petruski-Ivleva N, Madziva D, Cook C et al (2023) Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults. Ann Rheum Dis 82(7):957–962CrossRefPubMed
5.
go back to reference Gupta N, Mathew J, Mohan H, Chowdhury SD, Kurien RT, Christopher DJ et al (2018) Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India. Rheumatol Int 38(2):203–209CrossRefPubMed Gupta N, Mathew J, Mohan H, Chowdhury SD, Kurien RT, Christopher DJ et al (2018) Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India. Rheumatol Int 38(2):203–209CrossRefPubMed
6.
go back to reference Kamisawa T, Okazaki K (2016) Diagnosis and treatment of IgG4-related disease. In: Okazaki K (ed) IgG4-Related Disease [Internet]. Cham: Springer International Publishing [cited 2023 Jul 13]. p. 19–33. (Current Topics in Microbiology and Immunology; vol. 401). Available from: http://link.springer.com/10.1007/82_2016_36 Kamisawa T, Okazaki K (2016) Diagnosis and treatment of IgG4-related disease. In: Okazaki K (ed) IgG4-Related Disease [Internet]. Cham: Springer International Publishing [cited 2023 Jul 13]. p. 19–33. (Current Topics in Microbiology and Immunology; vol. 401). Available from: http://​link.​springer.​com/​10.​1007/​82_​2016_​36
8.
go back to reference Prabhu SM, Yadav V, Irodi A, Mani S, Varghese AM (2014) IgG4-related disease with sinonasal involvement: a case series. Indian J Radiol Imaging 24(2):117–120CrossRefPubMedPubMedCentral Prabhu SM, Yadav V, Irodi A, Mani S, Varghese AM (2014) IgG4-related disease with sinonasal involvement: a case series. Indian J Radiol Imaging 24(2):117–120CrossRefPubMedPubMedCentral
9.
go back to reference Rohan A, Ravishankar B, Vishwanath S, Vankalakunti M, Kishore B, Ballal H (2014) IgG4 related renal disease: a wolf in sheep’s clothing. Indian J Nephrol 24(6):382CrossRefPubMedPubMedCentral Rohan A, Ravishankar B, Vishwanath S, Vankalakunti M, Kishore B, Ballal H (2014) IgG4 related renal disease: a wolf in sheep’s clothing. Indian J Nephrol 24(6):382CrossRefPubMedPubMedCentral
10.
go back to reference Perugino CA, Mattoo H, Mahajan VS, Maehara T, Wallace ZS, Pillai S et al (2017) Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies: etiology and treatment of IgG4-RD. Arthritis Rheumatol 69(9):1722–1732CrossRefPubMedPubMedCentral Perugino CA, Mattoo H, Mahajan VS, Maehara T, Wallace ZS, Pillai S et al (2017) Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies: etiology and treatment of IgG4-RD. Arthritis Rheumatol 69(9):1722–1732CrossRefPubMedPubMedCentral
11.
go back to reference Mattoo H, Mahajan VS, Maehara T, Deshpande V, Della-Torre E, Wallace ZS et al (2016) Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 138(3):825–838CrossRefPubMedPubMedCentral Mattoo H, Mahajan VS, Maehara T, Deshpande V, Della-Torre E, Wallace ZS et al (2016) Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 138(3):825–838CrossRefPubMedPubMedCentral
12.
go back to reference Haldar D, Hirschfield GM (2018)Deciphering the biology of IgG4-related disease: specific antigens and disease? Gut 67(4):602–605 Haldar D, Hirschfield GM (2018)Deciphering the biology of IgG4-related disease: specific antigens and disease? Gut 67(4):602–605
13.
go back to reference Della-Torre E, Feeney E, Deshpande V, Mattoo H, Mahajan V, Kulikova M et al (2015) B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Ann Rheum Dis 74(12):2236–2243CrossRefPubMed Della-Torre E, Feeney E, Deshpande V, Mattoo H, Mahajan V, Kulikova M et al (2015) B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Ann Rheum Dis 74(12):2236–2243CrossRefPubMed
14.
go back to reference Della-Torre E, Rigamonti E, Perugino C, Baghai-Sain S, Sun N, Kaneko N et al (2020) B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. J Allergy Clin Immunol 145(3):968–981.e14CrossRefPubMed Della-Torre E, Rigamonti E, Perugino C, Baghai-Sain S, Sun N, Kaneko N et al (2020) B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. J Allergy Clin Immunol 145(3):968–981.e14CrossRefPubMed
15.
go back to reference Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA et al (2015) Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 74(6):1171–1177CrossRefPubMed Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA et al (2015) Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 74(6):1171–1177CrossRefPubMed
16.
go back to reference Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease: international consensus statement on IgG4-RD management. Arthritis Rheumatol 67(7):1688–1699CrossRefPubMed Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease: international consensus statement on IgG4-RD management. Arthritis Rheumatol 67(7):1688–1699CrossRefPubMed
18.
go back to reference Nambiar S, Oliver TI (2023) IgG4-related disease. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL). StatPearls Publishing Nambiar S, Oliver TI (2023) IgG4-related disease. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL). StatPearls Publishing
21.
go back to reference Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH (2015) The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 74(1):14–18CrossRefPubMed Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH (2015) The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 74(1):14–18CrossRefPubMed
22.
go back to reference Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T et al (2012) Consensus statement on the pathology of IgG4-related disease. Modern Pathol 25(9):1181–1192CrossRef Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T et al (2012) Consensus statement on the pathology of IgG4-related disease. Modern Pathol 25(9):1181–1192CrossRef
23.
go back to reference Ryu JH, Horie R, Sekiguchi H, Peikert T, Yi ES (2012) Spectrum of disorders associated with elevated serum IgG4 levels encountered in clinical practice. Int J Rheumatol 2012:1–6CrossRef Ryu JH, Horie R, Sekiguchi H, Peikert T, Yi ES (2012) Spectrum of disorders associated with elevated serum IgG4 levels encountered in clinical practice. Int J Rheumatol 2012:1–6CrossRef
24.
go back to reference Kamisawa T, Okamoto A, Funata N (2005) Clinicopathological features of autoimmune pancreatitis in relation to elevation of serum IgG4. Pancreas 31(1):28–31CrossRefPubMed Kamisawa T, Okamoto A, Funata N (2005) Clinicopathological features of autoimmune pancreatitis in relation to elevation of serum IgG4. Pancreas 31(1):28–31CrossRefPubMed
25.
go back to reference Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K et al (2011) Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med 50(2):69–75CrossRefPubMed Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K et al (2011) Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med 50(2):69–75CrossRefPubMed
26.
go back to reference Campochiaro C, Ramirez G, Bozzolo E, Lanzillotta M, Berti A, Baldissera E et al (2016) IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scand J Rheumatol 45(2):135–145CrossRefPubMed Campochiaro C, Ramirez G, Bozzolo E, Lanzillotta M, Berti A, Baldissera E et al (2016) IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scand J Rheumatol 45(2):135–145CrossRefPubMed
27.
go back to reference Kasashima S, Kawashima A, Kasashima F, Endo M, Matsumoto Y, Kawakami K (2018) Inflammatory features, including symptoms, increased serum interleukin-6, and C-reactive protein, in IgG4-related vascular diseases. Heart Vessels 33(12):1471–1481CrossRefPubMed Kasashima S, Kawashima A, Kasashima F, Endo M, Matsumoto Y, Kawakami K (2018) Inflammatory features, including symptoms, increased serum interleukin-6, and C-reactive protein, in IgG4-related vascular diseases. Heart Vessels 33(12):1471–1481CrossRefPubMed
28.
go back to reference Carruthers MN, Stone JH, Deshpande V, Khosroshahi A (2012) Development of an IgG4-RD responder index. Int J Rheumatol 2012:1–7CrossRef Carruthers MN, Stone JH, Deshpande V, Khosroshahi A (2012) Development of an IgG4-RD responder index. Int J Rheumatol 2012:1–7CrossRef
29.
go back to reference Handa T, Matsui S, Yoshifuji H, Kodama Y, Yamamoto H, Minamoto S et al (2018) Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. Modern Rheumatol 28(5):838–844CrossRef Handa T, Matsui S, Yoshifuji H, Kodama Y, Yamamoto H, Minamoto S et al (2018) Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease. Modern Rheumatol 28(5):838–844CrossRef
30.
go back to reference Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS et al (2014) De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol 134(3):679–687CrossRefPubMedPubMedCentral Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS et al (2014) De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol 134(3):679–687CrossRefPubMedPubMedCentral
31.
go back to reference Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H et al (2015) Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 74(1):190–195CrossRefPubMed Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H et al (2015) Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 74(1):190–195CrossRefPubMed
32.
go back to reference Nada R, Ramachandran R, Kumar A, Rathi M, Rawat A, Joshi K et al (2016) IgG4-related tubulointerstitial nephritis: a prospective analysis. Int J Rheum Dis 19(7):721–729CrossRefPubMed Nada R, Ramachandran R, Kumar A, Rathi M, Rawat A, Joshi K et al (2016) IgG4-related tubulointerstitial nephritis: a prospective analysis. Int J Rheum Dis 19(7):721–729CrossRefPubMed
33.
go back to reference Chougule A, Bal A, Das A, Singh G (2015) IgG4 related sclerosing mastitis: expanding the morphological spectrum of IgG4 related diseases. Pathology 47(1):27–33CrossRefPubMed Chougule A, Bal A, Das A, Singh G (2015) IgG4 related sclerosing mastitis: expanding the morphological spectrum of IgG4 related diseases. Pathology 47(1):27–33CrossRefPubMed
34.
go back to reference Yoshikawa T, Watanabe T, Minaga K, Kamata K, Kudo M (2019) Cytokines produced by innate immune cells in IgG4-related disease. Modern Rheumatol 29(2):219–225CrossRef Yoshikawa T, Watanabe T, Minaga K, Kamata K, Kudo M (2019) Cytokines produced by innate immune cells in IgG4-related disease. Modern Rheumatol 29(2):219–225CrossRef
35.
go back to reference Lighaam LC, Aalberse RC, Rispens T (2012) IgG4-related fibrotic diseases from an immunological perspective: regulators out of control? Int J Rheumatol 2012:1–6CrossRef Lighaam LC, Aalberse RC, Rispens T (2012) IgG4-related fibrotic diseases from an immunological perspective: regulators out of control? Int J Rheumatol 2012:1–6CrossRef
36.
go back to reference Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M et al (2007) Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 45(6):1538–1546CrossRefPubMed Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M et al (2007) Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 45(6):1538–1546CrossRefPubMed
37.
go back to reference Tanaka A, Moriyama M, Nakashima H, Miyake K, Hayashida JN, Maehara T et al (2012) Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheumatism 64(1):254–263CrossRefPubMed Tanaka A, Moriyama M, Nakashima H, Miyake K, Hayashida JN, Maehara T et al (2012) Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheumatism 64(1):254–263CrossRefPubMed
38.
go back to reference Akiyama M, Suzuki K, Yamaoka K, Yasuoka H, Takeshita M, Kaneko Y et al (2015) Brief report: number of circulating follicular helper 2 T cells correlates with IgG4 and Interleukin-4 levels and plasmablast numbers in IgG4-related disease: Tfh2 cells in IgG4-related disease. Arthritis Rheumatol 67(9):2476–2481CrossRefPubMed Akiyama M, Suzuki K, Yamaoka K, Yasuoka H, Takeshita M, Kaneko Y et al (2015) Brief report: number of circulating follicular helper 2 T cells correlates with IgG4 and Interleukin-4 levels and plasmablast numbers in IgG4-related disease: Tfh2 cells in IgG4-related disease. Arthritis Rheumatol 67(9):2476–2481CrossRefPubMed
39.
go back to reference Kamekura R, Takano K, Yamamoto M, Kawata K, Shigehara K, Jitsukawa S et al (2017) Cutting edge: a critical role of lesional T follicular helper cells in the pathogenesis of IgG4-related disease. J Immunol 199(8):2624–2629CrossRefPubMed Kamekura R, Takano K, Yamamoto M, Kawata K, Shigehara K, Jitsukawa S et al (2017) Cutting edge: a critical role of lesional T follicular helper cells in the pathogenesis of IgG4-related disease. J Immunol 199(8):2624–2629CrossRefPubMed
40.
go back to reference Maehara T, Mattoo H, Ohta M, Mahajan VS, Moriyama M, Yamauchi M et al (2017) Lesional CD4 + IFN-γ + cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Ann Rheum Dis 76(2):377–385CrossRefPubMed Maehara T, Mattoo H, Ohta M, Mahajan VS, Moriyama M, Yamauchi M et al (2017) Lesional CD4 + IFN-γ + cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Ann Rheum Dis 76(2):377–385CrossRefPubMed
41.
go back to reference Watanabe T, Yamashita K, Kudo M (2016) IgG4-related disease and innate immunity. In: Okazaki K (ed) IgG4-related disease [Internet]. Cham: Springer International Publishing [cited 2023 Jul 18]. p. 115–28. (Current Topics in Microbiology and Immunology; vol. 401). Available from: http://link.springer.com/10.1007/82_2016_42 Watanabe T, Yamashita K, Kudo M (2016) IgG4-related disease and innate immunity. In: Okazaki K (ed) IgG4-related disease [Internet]. Cham: Springer International Publishing [cited 2023 Jul 18]. p. 115–28. (Current Topics in Microbiology and Immunology; vol. 401). Available from: http://​link.​springer.​com/​10.​1007/​82_​2016_​42
42.
go back to reference Ishiguro N, Moriyama M, Furusho K, Furukawa S, Shibata T, Murakami Y et al (2020) Activated M2 macrophages contribute to the pathogenesis of IgG4-related disease via toll-like receptor 7/interleukin-33 signaling. Arthritis Rheumatol 72(1):166–178CrossRefPubMed Ishiguro N, Moriyama M, Furusho K, Furukawa S, Shibata T, Murakami Y et al (2020) Activated M2 macrophages contribute to the pathogenesis of IgG4-related disease via toll-like receptor 7/interleukin-33 signaling. Arthritis Rheumatol 72(1):166–178CrossRefPubMed
Metadata
Title
Myofibroblast and pro-fibrotic cytokines in fibrosis of IgG4-related disease (IgG4-RD) patients from South Asia: preliminary data
Authors
Josna Joseph
V. Prabhu
Meera Thomas
Reka Karuppusami
Thomas Alex Kodiatte
Rajiv Michael
Manbha L. Rymbai
John Mathew
Publication date
03-02-2024
Publisher
Springer International Publishing
Keyword
Cytokines
Published in
Clinical Rheumatology / Issue 3/2024
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-023-06861-9

Other articles of this Issue 3/2024

Clinical Rheumatology 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.